Adverse events associated with immune checkpoint inhibitor treatment for cancer

Key points Inhibitors against cytotoxic T-lymphocyte–associated protein 4 and programmed cell death 1 immune checkpoints are novel agents that modulate immune pathways and enhance anti-tumour immunity. Their use has set new standards in the treatment of many cancer types. Some patients with